Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 19, 2023 - Issue 2
Submit an article Journal homepage
1,225
Views
1
CrossRef citations to date
0
Altmetric
Editorial

A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens

Rachel Chevaliera University of Missouri School of Medicine, Kansas, MO, USA;b Children’s Mercy Kansas City, Division of Gastroenterology, Hepatology and Nutrition, Kansas City, MO, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7628-6007View further author information
ORCID Icon,
Thomas Attarda University of Missouri School of Medicine, Kansas, MO, USA;b Children’s Mercy Kansas City, Division of Gastroenterology, Hepatology and Nutrition, Kansas City, MO, USAORCID Iconhttps://orcid.org/0000-0002-7480-4437View further author information
ORCID Icon,
Sara L Van Driestc Department of Pediatrics, Center for Pediatric Precision Medicine, Nashville, TN, USAView further author information
&
Valentina Shakhnovicha University of Missouri School of Medicine, Kansas, MO, USA;b Children’s Mercy Kansas City, Division of Gastroenterology, Hepatology and Nutrition, Kansas City, MO, USAORCID Iconhttps://orcid.org/0000-0003-3744-648XView further author information
ORCID Icon
Pages 53-56 | Received 31 Aug 2022, Accepted 07 Mar 2023, Published online: 23 Mar 2023

References

  • Poly TN, Lin MC, Syed-Abdul S, et al. Proton pump inhibitor use and risk of gastric cancer: current evidence from epidemiological studies and critical appraisal. Cancers (Basel). 2022;14:13.
  • Sheridan K. Heartburn and acid reflux drugs double risk of stomach cancer 2017 [Cited 2022 Aug 16]. Available from: https://www.newsweek.com/heartburn-and-acid-reflux-drugs-double-risk-stomach-cancer-699596.
  • Yibirin M, De Oliveira D, Valera R, et al. Adverse effects associated with proton pump inhibitor use. Cureus. 2021;13(1):e12759.
  • Hall M, Attard TM, Berry JG. Improving cohort definitions in research using hospital administrative databases-do we need guidelines? JAMA Pediatr. 2022;176(6):539–540.
  • Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2021;109(6):1417–1423.
  • Yucel E, Sancar M, Yucel A, et al. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Saf. 2016;15(2):223–236.
  • Lima JJ, Lang JE, Mougey EB, et al. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr. 2013;163(3):686–691.
  • Bernal CJ, Aka I, Carroll RJ, et al. CYP2C19 phenotype and risk of proton pump inhibitor-associated infections. Pediatrics. 2019;144(6):6.
  • Cicali EJ, Blake K, Gong Y, et al. Novel implementation of genotype-guided proton pump inhibitor medication therapy in children: a pilot, randomized, multisite pragmatic trial. Clin Transl Sci. 2019;12(2):172–179.
  • Ohkusa T, Maekawa T, Arakawa T, et al. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther. 2005;21(11):1331–1339.
  • Gronich N, Lavi I, Lejbkowicz F, et al. Association of CYP2C19 polymorphism with proton pump inhibitors effectiveness and with fractures in real-life: retrospective cohort study. Clin Pharmacol Ther. 2022;111(5):1084–1092.
  • Helsby NA, Lo WY, Simpson IJ, et al. Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype. Br J Clin Pharmacol. 2010;69(5):516–519.
  • Lutz M, Schwab M, Griese EU, et al. Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism. Pharmacogenetics. 2002;12(1):73–75.
  • Pisanu C, Welander NZ, Rukh G, et al. Association between migraine prevalence, treatment with proton-pump inhibitors and CYP2C19 phenotypes in UK Biobank. Biomed Pharmacother. 2021;143:112234.
  • Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther. 2001;15(9):1479–1484.
  • El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447–460. Epub 20180412

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.